Clinical trial
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
NCT00319618 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00319618 |
|---|---|
| Title | Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer |
| Official title | A Randomised Phase II Study: Treatment With Daily p.o. Iressa™ (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Docetaxel |
| Enrollment | 66 |
| Start date | Jun 1, 2003 |
| Completion | Jun 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Dec 18, 2007 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: